Vaxcyte, Inc. PCVX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $262.31M-24.7% | $175.43M-54.9% | $282.55M-73.1% | $308.06M-40.7% | $348.17M-43.2% | ||
| $1.48B+11.4% | $1.39B+2.0% | $1.43B+26.5% | $1.35B+45.0% | $1.32B+51.4% | ||
| $1.81B+5.6% | $1.63B-9.0% | $1.77B-20.2% | $1.72B+15.8% | $1.72B+13.1% | ||
| $260.7M+20.1% | $257.37M+30.0% | $253.49M+55.3% | $242.27M+92.3% | $217.16M+156% | ||
| $1.53B-7.6% | $1.38B-20.2% | $1.4B+4.4% | $1.59B+162% | $1.66B+189% | ||
| $3.35B-0.9% | $3B-14.5% | $3.17B-10.9% | $3.31B+58.4% | $3.38B+61.5% | ||
| $214.34M+119% | $171.79M+73.8% | $149.34M+130% | $118.6M+89.8% | $97.65M+43.0% | ||
| $242.08M+150% | $205.75M+46.8% | $200.05M+61.6% | $154.49M+86.5% | $97M+11.4% | ||
| $352.29M+97.8% | $317.21M+54.4% | $278.72M+96.1% | $234.03M+131% | $178.08M+65.9% | ||
| 500M0.0% | 500M+390,525% | 500M0.0% | 500M0.0% | 500M0.0% | ||
| -$2.48B-61.9% | -$2.15B-55.2% | -$1.91B-52.5% | -$1.7B-47.7% | -$1.53B-50.0% | ||
| $3B-6.4% | $2.69B-18.8% | $2.89B-15.4% | $3.07B+54.6% | $3.2B+61.3% | ||
| $3.35B-0.9% | $3B-14.5% | $3.17B-10.9% | $3.31B+58.4% | $3.38B+61.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vaxcyte, Inc.'s total assets?
- Vaxcyte, Inc. (PCVX) holds $3.3B in total assets, down 0.9% year over year.
- How much debt does Vaxcyte, Inc. have?
- Vaxcyte, Inc. carries $116.3M in total debt against $3.0B of shareholders' equity, a debt-to-equity ratio of 0.04.
- How much cash does Vaxcyte, Inc. have?
- Vaxcyte, Inc. holds $262.3M in cash and equivalents.
- Can Vaxcyte, Inc. cover its short-term obligations?
- Its current ratio is 7.49 — current assets exceed current liabilities.
- Where does Vaxcyte, Inc.'s balance sheet data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.